Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
作者信息
Xu Xiaoqian, You Hong, Jia Jidong, Kong Yuanyuan
机构信息
National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, Beijing, China.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):994-996. doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Clin Mol Hepatol. 2024 Oct;30(4):994-996. doi: 10.3350/cmh.2024.0552. Epub 2024 Jul 23.
2
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Clin Mol Hepatol. 2024 Oct;30(4):656-658. doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.
3
Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy.
World J Gastroenterol. 2021 Mar 21;27(11):1101-1116. doi: 10.3748/wjg.v27.i11.1101.
4
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10.
5
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
J Hepatol. 2018 Nov;69(5):1066-1073. doi: 10.1016/j.jhep.2018.07.018. Epub 2018 Aug 1.
6
[Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):297-300. doi: 10.3760/cma.j.cn501113-20210409-00175.
7
Long-Term Prediction Model for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Antiviral Therapy: Based on Data from Korean Patients.
J Clin Med. 2022 Nov 8;11(22):6613. doi: 10.3390/jcm11226613.
8
Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Receiving Finite Periods of Antiviral Therapy.
Cancers (Basel). 2023 Jun 25;15(13):3343. doi: 10.3390/cancers15133343.
9
PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.
J Hepatol. 2024 Jan;80(1):20-30. doi: 10.1016/j.jhep.2023.09.011. Epub 2023 Sep 19.
10
Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101930. doi: 10.1016/j.clinre.2022.101930. Epub 2022 Apr 20.
引用本文的文献
1
Prediction Model for Familial Aggregated HBV-Associated Hepatocellular Carcinoma Based on Serum Biomarkers.
Cancer Rep (Hoboken). 2025 Jun;8(6):e70253. doi: 10.1002/cnr2.70253.
2
Reply to correspondence on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Clin Mol Hepatol. 2024 Oct;30(4):1044-1046. doi: 10.3350/cmh.2024.0584. Epub 2024 Jul 29.
本文引用的文献
1
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on "Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients".
Clin Mol Hepatol. 2024 Oct;30(4):656-658. doi: 10.3350/cmh.2024.0499. Epub 2024 Jul 8.
2
Long-term antiviral therapy is associated with changes in the profile of transcriptionally active HBV integration in the livers of patients with CHB.
J Med Virol. 2024 Jun;96(6):e29606. doi: 10.1002/jmv.29606.
3
Prediagnostic plasma metabolite concentrations and liver cancer risk: a population-based study of Chinese men.
EBioMedicine. 2024 Feb;100:104990. doi: 10.1016/j.ebiom.2024.104990. Epub 2024 Feb 1.
4
Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma.
Nat Commun. 2023 Dec 18;14(1):8392. doi: 10.1038/s41467-023-44255-2.
5
Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection.
Clin Mol Hepatol. 2023 Oct;29(4):1029-1042. doi: 10.3350/cmh.2023.0190. Epub 2023 Aug 29.
6
Dynamic changes in three biomarkers predict early-stage hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.
J Cancer Res Clin Oncol. 2023 Nov;149(14):12691-12701. doi: 10.1007/s00432-023-05024-2. Epub 2023 Jul 15.
7
Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
J Hepatol. 2023 Oct;79(4):933-944. doi: 10.1016/j.jhep.2023.05.039. Epub 2023 Jun 10.
8
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10.
9
Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients.
Clin Gastroenterol Hepatol. 2023 Oct;21(11):2864-2875.e16. doi: 10.1016/j.cgh.2023.02.004. Epub 2023 Feb 22.
10
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.
Nat Rev Gastroenterol Hepatol. 2022 Nov;19(11):727-745. doi: 10.1038/s41575-022-00649-z. Epub 2022 Jul 20.
Zotero 插件